The ichthyoses are a large, heterogeneous group of skin cornification disorders. They can
be inherited or acquired, and result in defective keratinocyte differentiation and abnormal …

Introduction Patients with moderate-to-severe psoriasis (PsO) treated with interleukin (IL)-
inhibitors may require treatment modification to achieve disease control. This study …

Background and objective Real-world evidence on persistence of interleukin-17 inhibitors
(IL-17i) as a drug class among Japanese patients with psoriasis is lacking. Hence, we aimed …

Objective Plaque psoriasis is a chronic, inflammatory, immune-mediated skin disease.
Biologic therapies markedly improve skin disease severity and health-related quality of life …

Introduction and aim Psoriasis vulgaris is associated with a significant healthcare burden,
which increases over time as the disease progresses. The aim of this retrospective …

Background With advent of newer treatments for psoriasis, real-world use of biologics in
Japan is evolving. Methods This retrospective study utilized data from patients with≥ 1 …

A 52‐week postmarketing surveillance study was initiated to evaluate the safety and
effectiveness of guselkumab, a human anti–interleukin 23 subunit p19 monoclonal antibody …

Introduction Due to variable psoriasis symptoms, disease progression, and individual
responses to therapy, patients may start, stop, or switch biologic therapies. Real-world data …

Introduction Poor persistence to biologics can result in suboptimal health outcomes and
increased economic burden for chronic conditions, including psoriasis (PsO). In Japan …

Plaque psoriasis (PsO) is a chronic immune‐mediated inflammatory disease with skin
lesions accompanied by an inflammation‐related comorbidity risk. The development of …